CCK Stock Recent News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

LOS ANGELES, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Crown Electrokinetics Corp. (NASDAQ: CRKN) ("Crown" or the "Company”), a leading provider of innovative technology infrastructure solutions that benefit communities and the environment, today announced that its Water Solutions division has successfully completed construction of the first of two slant wells at the Twin Dolphin Club in Cabo San Lucas, Mexico.

LOS ANGELES, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Crown Electrokinetics Corp. (NASDAQ: CRKN) ("Crown" or the "Company”), a leading provider of innovative technology infrastructure solutions that benefit communities and the environment, today announced that its Element 82 division has secured two new lead pipe inspection projects in New York. With completed and active projects in the state of New York, Element 82 is expanding its lead inspection footprint into the city of Little Falls and town of Warwick.

Crown Castle (CCI) stock is trading near 52-week lows, presenting an attractive entry point for long-term investors with a robust 6.45% dividend yield. CCI's strategic focus on small cells and 5G infrastructure positions it for significant long-term growth, despite current macroeconomic challenges and high capex demands. The company's optimization efforts, including cost-cutting and asset prioritization, have bolstered its financial performance, with impressive profitability metrics and a strong balance sheet.

Investors need to pay close attention to Crown Holdings (CCK) stock based on the movements in the options market lately.

Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn. , Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC) at a price of $3.10 per share in cash.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought for $3.10 per share by privately held Crown Laboratories, instead of $6.66 per share agreed previously, the two companies said on Monday.

In Partnership With Mexico's 529 Capital, A Leading Real Estate Development Firm From The Baja Peninsula Expected To Produce Up To An Estimated $40 Million In Recurring Annual Revenue LOS ANGELES, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Crown Electrokinetics Corp. (NASDAQ: CRKN) ("Crown" or the "Company”), a leading provider of innovative technology infrastructure solutions that benefit communities and the environment, today announced that its Water Solutions division plans to construct and co-own a state-of-the-art reverse osmosis (RO) water treatment plant in Cabo San Lucas, Mexico for the desalination of water collected from its proprietary design slant wells. The new RO plant will be built and owned in partnership with locally based, 529 Capital, a leading real estate development firm in the Baja Peninsula.

JOHNSON CITY, Tenn. and NASHVILLE, Tenn.